Back to top

November 2015

  /  2015

Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.  

Kathrin Strasser-Weippl, Yanin Chavarri-Guerra, Cynthia Villarreal-Garza, Brittany L Bychkovsky, Marcio Debiasi, Pedro E R Liedke, Enrique Soto-Perez-de-Celis, Don Dizon, Eduardo Cazap, Gilberto de Lima Lopes Jr, Diego Touya, Jo?o Soares Nunes, Jessica St Louis, Caroline Vail, Alexandra Bukowski, Pier Ramos-Elias, Karla Unger-Saldaña, Denise Froes Brandao, Mayra E Ferreyra, Silvana Luciani, Angelica Nogueira-Rodrigues, Aknar Freire de Carvalho Calabrich, Marcela G Del Carmen, Jose Alejandro Rauh-Hain, Kathleen Schmeler, Raúl Sala, Paul E Goss DOI: Lancet Oncol 2015; 16: 1405-38 Full link: http://www.thelancet.com/commissions/latin-america